Neurocrine Biosciences (NBIX) Capital Expenditures Growth (5y) (2015 - 2026)
Neurocrine Biosciences (NBIX) Capital Expenditures Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.33 Bn | 2.15 Bn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.15 Bn | 19.48 Bn | 683.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.74 Bn | 11.21 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - |
| 10 | Alkermes | 8.11 Bn | 7.46 Bn | 397.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.65% |
| Mar 31, 2026 | 69.52% |
| Dec 31, 2025 | -17.55% |
| Sep 30, 2025 | 180.13% |
| Jun 30, 2025 | -145.95% |
| Mar 31, 2025 | 67.98% |
| Dec 31, 2024 | 40.27% |
| Sep 30, 2024 | -17.37% |
| Jun 30, 2024 | -95.19% |
| Mar 31, 2024 | 79.56% |
| Dec 31, 2023 | -41.32% |
| Sep 30, 2023 | 15.12% |
| Jun 30, 2023 | -50.07% |
| Dec 31, 2022 | -51.15% |
| Sep 30, 2022 | 24.77% |
| Jun 30, 2022 | -6.88% |
| Mar 31, 2022 | 15.50% |
| Dec 31, 2021 | 34.28% |
| Sep 30, 2021 | 73.74% |
| Jun 30, 2021 | -1.31% |